Table 1 Incidence rate and excess risk attributable to statins for myopathy, hepatic disorder and diabetes

Myopathy

Gaist et al.[50]

2.30

2.10

One prescription and additional 30 days supply

Medical codes for myopathic events and validation by independent blind review of medical records

(1.20 to 4.40)

Hippisley-Cox et al.[55]

0.26%

0.22%

First prescription after January 2002

Medical codes for moderate or serious myopathic events (myopathy or rhabdomyolysis or a CK ≥4X ULN)

(0.24% to 0.28%)

McClure et al.[77]

9.06

5.77

One prescription during the study period

Medical codes for myopathy and CK ≥10X ULN

(n.r.)

Smeeth et al.[94]

0.11%

0.08%

First prescription after January 1995

Medical codes for myositis or myolysis

(n.r.)

Hepatic disorder

Hippisley-Cox et al.[55]

1.20%

0.50%

First prescription after January 2002

ALT ≥120 IU/l among patients without chronic liver disease

(1.13% to 1.22%)

Smeeth et al.[94]

1.60%

0.30%

First prescription after January 1995

Medical codes for acute liver disease

First year only

0.44%

0.16%

(n.r.)

Diabetes

Culver et al.[41]

6.25%

2.25%

One prescription at the first screening interview and three-year follow-up

Self-report of a new physician diagnosis of treated diabetes

(5.71% to 6.84%)

Jick et al.[59]

n.a.

n.a.

Two prescriptions one year before index date

Medical code for first diagnosis of diabetes plus more than two prescriptions for a hypoglycaemic agent or three records of diet management